{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:55:48Z","timestamp":1792176948410,"version":"4.4.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"34","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The value of p16\/Ki67 dual staining in differentiating patients with high-risk HPV infection","award":["(2024S13)"],"award-info":[{"award-number":["(2024S13)"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,21]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Cervical cancer is closely associated with persistent infection by high-risk human papillomavirus (hrHPV). Although HPV testing offers high sensitivity, its limited specificity may result in excessive colposcopy referrals, and the triage performance of traditional liquid-based cytology (TCT) remains suboptimal among hrHPV-positive women. As a biomarker reflecting HPV-mediated cell-cycle dysregulation and aberrant proliferation, p16\/Ki-67 dual staining has shown potential advantages in identifying clinically significant high-grade cervical lesions. This study aimed to evaluate the clinical utility of p16\/Ki-67 dual staining in screening cervical lesions among hrHPV-positive women and to explore its role in optimizing referral strategies. Retrospectively, this single-center cohort study included 100 consecutive hrHPV-positive women who attended our clinic between October 2024 and October 2025. All participants underwent hrHPV genotyping, TCT, and p16\/Ki-67 dual staining during the same visit, followed by colposcopy and histopathological assessment. Histology served as the reference standard. We evaluated the diagnostic performance of p16\/Ki-67 for cervical intraepithelial neoplasia 2+ (CIN2+) lesions and compared it with TCT, HPV genotyping, and a combined triage model (hrHPV\u2005+\u2005TCT\u2005+\u2005p16\/Ki-67). In addition, we simulated the screening efficiency of different colposcopy referral strategies. Among the 100 hrHPV-positive women included, 35 (35.0%) were diagnosed with CIN2+. The prevalence of HPV16 infection and the positivity rate of p16\/Ki-67 dual staining were significantly higher in the CIN2+ group than in the non-CIN2+ group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.01). For CIN2+ detection, p16\/Ki-67 dual staining demonstrated a sensitivity of 88.6%, a specificity of 78.5%, and a negative predictive value of 93.0%. Dual-stain positivity increased progressively with cytological severity and provided meaningful triage value across atypical squamous cells of undetermined significance, low-grade squamous intraepithelial lesion, and high-grade squamous intraepithelial lesion categories. The combined triage model yielded the best diagnostic performance, with an area under the curve of 0.91. Using \u201cdual-stain positivity or TCT\u2005\u2265\u2005atypical squamous cells of undetermined significance\u201d as the referral threshold substantially reduced the colposcopy referral rate while maintaining a high CIN2+ detection rate. p16\/Ki-67 dual staining provides high diagnostic accuracy and strong negative predictive capability for CIN2+ lesions among hrHPV-positive women. Integrating p16\/Ki-67 dual staining with TCT and HPV genotyping can markedly improve screening precision and optimize colposcopy referral strategies, thereby reducing unnecessary invasive procedures and demonstrating promising clinical applicability.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050102","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T17:06:00Z","timestamp":1787331960000},"page":"e50102","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Analysis of the clinical utility of p16\/Ki-67 dual staining in screening cervical lesions among women positive for high-risk HPV"],"prefix":"10.1097","volume":"105","author":[{"given":"Qingsong","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, Cangnan Hospital of Traditional Chinese Medicine, Cangnan County, Wenzhou, Zhejiang Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Cangnan Hospital of Traditional Chinese Medicine, Cangnan County, Wenzhou, Zhejiang Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leilei","family":"Bao","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Cangnan Hospital of Traditional Chinese Medicine, Cangnan County, Wenzhou, Zhejiang Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2105-3353","authenticated-orcid":false,"given":"Qiuyang","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Cangnan Hospital of Traditional Chinese Medicine, Cangnan County, Wenzhou, Zhejiang Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260917","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/S2214-109X(19)30482-6","article-title":"Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis.","volume":"8","author":"Arbyn","year":"2020","journal-title":"Lancet Glob Health"},{"key":"R2-20260917","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0140-6736(07)61416-0","article-title":"Human papillomavirus and cervical cancer.","volume":"370","author":"Schiffman","year":"2007","journal-title":"Lancet"},{"key":"R3-20260917","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0140-6736(24)01097-3","article-title":"Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature.","volume":"404","author":"Wei","year":"2024","journal-title":"Lancet"},{"key":"R4-20260917","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(08)70103-7","article-title":"Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study.","volume":"9","author":"McCredie","year":"2008","journal-title":"Lancet Oncol"},{"key":"R5-20260917","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1001\/jama.287.16.2114","article-title":"The 2001 Bethesda system: terminology for reporting results of cervical cytology.","volume":"287","author":"Solomon","year":"2002","journal-title":"JAMA"},{"key":"R6-20260917","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/ijc.30454","article-title":"HPV for cervical cancer screening (HPV FOCAL): complete round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer.","volume":"140","author":"Ogilvie","year":"2017","journal-title":"Int J Cancer"},{"key":"R7-20260917","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","article-title":"Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials.","volume":"383","author":"Ronco","year":"2014","journal-title":"Lancet"},{"key":"R8-20260917","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00428-005-0141-x","article-title":"p16INK4A overexpression and HPV infection in uterine cervix adenocarcinoma.","volume":"448","author":"Missaoui","year":"2006","journal-title":"Virchows Arch"},{"key":"R9-20260917","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/modpathol.2016.80","article-title":"p16\/Ki-67 dual-stained cytology for detecting cervical (pre)cancer in a HPV-positive gynecologic outpatient population.","volume":"29","author":"Luttmer","year":"2016","journal-title":"Mod Pathol"},{"key":"R10-20260917","doi-asserted-by":"crossref","first-page":"245","DOI":"10.5144\/0256-4947.2016.245","article-title":"Predictive value of p16\/Ki-67 immunocytochemistry for triage of women with abnormal papanicolaou test in cervical cancer screening: a systematic review and meta-analysis.","volume":"36","author":"Chen","year":"2016","journal-title":"Ann Saudi Med"},{"key":"R11-20260917","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000475979","article-title":"p16\/Ki-67 immunocytochemistry in gynecological cytology: limitations in practice.","volume":"61","author":"Ziemke","year":"2017","journal-title":"Acta Cytol"},{"key":"R12-20260917","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/dc.24339","article-title":"p16\/Ki-67 immunostaining in the triage of young women with LSIL, ASC-US, and ASC-H cytology.","volume":"48","author":"Dovnik","year":"2020","journal-title":"Diagn Cytopathol"},{"key":"R13-20260917","doi-asserted-by":"crossref","first-page":"815213","DOI":"10.3389\/fonc.2021.815213","article-title":"A comparative study on the accuracy and efficacy between Dalton and CINtec\u00ae PLUS p16\/Ki-67 dual stain in triaging HPV-positive women.","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"R14-20260917","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/LGT.0000000000000525","article-title":"2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors.","volume":"24","author":"Perkins","year":"2020","journal-title":"J Low Genit Tract Dis"},{"key":"R15-20260917","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/cncy.20140","article-title":"p16\/Ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: results from the European equivocal or mildly abnormal papanicolaou cytology study.","volume":"119","author":"Schmidt","year":"2011","journal-title":"Cancer Cytopathol"},{"key":"R16-20260917","doi-asserted-by":"crossref","first-page":"djv257","DOI":"10.1093\/jnci\/djv257","article-title":"p16\/Ki-67 dual stain cytology for detection of cervical precancer in HPV-positive women.","volume":"107","author":"Wentzensen","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"R17-20260917","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/dc.24427","article-title":"Good performance of p16\/Ki-67 dual-stain cytology for detection and post-treatment surveillance of high-grade CIN\/VAIN in a prospective, cross-sectional study.","volume":"48","author":"Liu","year":"2020","journal-title":"Diagn Cytopathol"},{"key":"R18-20260917","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/dc.25332","article-title":"Evaluation of dual p16\/Ki-67 immunostaining on anal cytology specimens.","volume":"52","author":"Smithgall","year":"2024","journal-title":"Diagn Cytopathol"},{"key":"R19-20260917","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer.","volume":"348","author":"Mu\u00f1oz","year":"2003","journal-title":"N Engl J Med"},{"key":"R20-20260917","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial.","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"key":"R21-20260917","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.jogc.2018.08.004","article-title":"Post-colposcopy management of ASC-US and LSIL pap tests (PALS trial): pilot RCT.","volume":"41","author":"Saciragic","year":"2019","journal-title":"J Obstet Gynaecol Can"},{"key":"R22-20260917","doi-asserted-by":"crossref","first-page":"e70404","DOI":"10.1002\/jmv.70404","article-title":"Risk-based triage strategy by extended HPV genotyping for women with LSIL cytology: a real-world study.","volume":"97","author":"Ye","year":"2025","journal-title":"J Med Virol"},{"key":"R23-20260917","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/ijc.31261","article-title":"Eurogin roadmap 2017: triage strategies for the management of HPV-positive women in cervical screening programs.","volume":"143","author":"Cuschieri","year":"2018","journal-title":"Int J Cancer"},{"key":"R24-20260917","first-page":"173","article-title":"Colposcopy.","volume":"64","author":"Pretorius","year":"2012","journal-title":"Minerva Ginecol"},{"key":"R25-20260917","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s13224-020-01380-y","article-title":"Role of cervical cancer biomarkers p16 and Ki-67 in abnormal cervical cytological smear.","volume":"71","author":"Gothwal","year":"2021","journal-title":"J Obstet Gynaecol India"},{"key":"R26-20260917","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/LGT.0000000000000529","article-title":"Risk estimates supporting the 2019 ASCCP risk-based management consensus guidelines.","volume":"24","author":"Egemen","year":"2020","journal-title":"J Low Genit Tract Dis"},{"key":"R27-20260917","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.hoc.2024.03.005","article-title":"Cervical cancer: precursors and prevention.","volume":"38","author":"Sahasrabuddhe","year":"2024","journal-title":"Hematol Oncol Clin North Am"},{"key":"R28-20260917","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/0969141317704679","article-title":"Cost-effectiveness of strategies to increase cervical screening uptake at first invitation (STRATEGIC).","volume":"25","author":"Tsiachristas","year":"2018","journal-title":"J Med Screen"},{"key":"R29-20260917","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13148-023-01537-2","article-title":"DNA methylation as a triage marker for colposcopy referral in HPV-based cervical cancer screening: a systematic review and meta-analysis.","volume":"15","author":"Salta","year":"2023","journal-title":"Clin Epigenetics"},{"key":"R30-20260917","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ygyno.2011.02.033","article-title":"Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16\/Ki-67 dual-stained cytology.","volume":"121","author":"Petry","year":"2011","journal-title":"Gynecol Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050102","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:00:51Z","timestamp":1789624851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":30,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050102","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"2026-03-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}